(Investorideas.com
Newswire) a go-to platform for big investing ideas, including biotech
and medical tech stock issues a news and trading alert for Scinai
Immunotherapeutics Ltd. (NASDAQ: SCNI).
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) makes the Nasdaq top gainers list today, currently trading at
0.8867 +0.4307 (+94.45%) on a volume of 162 million shares as of
this report.
It looks like retail traders and promotions are pushing the stock
following news .
Scinai Immunotherapeutics today announced that it has entered into a
securities purchase agreement with an institutional life sciences
investor, as well as with new and existing institutional and
accredited investors, for the purchase and sale of 5,208,333
American Depositary Shares (ADSs), each representing 4,000 ordinary
shares, at a purchase price of $0.48 per ADS, as well as a Series A
warrant to purchase up to 5,208,333 ADSs at an exercise price of
$0.48 per ADS, exercisable immediately with a term of two years, and
a Series B warrant to purchase up to 5,208,333 ADSs at an exercise
price of $0.55 per ADS, exercisable immediately with a term of five
years.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of
innovative immunology therapies. The company is advancing a pipeline
of therapeutic candidates licensed from the Max Planck Society and
from PinCell S.r.l.
Scinai also owns Scinai Biopharma Services Ltd., a contract
development and manufacturing organization (CDMO), providing
development and manufacturing services to biotechnology and
pharmaceutical companies. www.scinai.com
About Investorideas.com – Where you find the best investing
ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking
stock news to top-rated investing podcasts, we cover it all. Our
original branded content includes podcasts such as Exploring Mining,
Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for sectors including mining, crypto,
renewable energy, gaming, biotech, tech, sports and more. Public
companies within the sectors we cover can use our news publishing and
content creation services to help tell their story to interested
investors. Paid content is always disclosed.
Disclaimer/Disclosure Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites
should be construed as an offer or solicitation to buy or sell products
or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is
posted for each compensated news release, content published/created if
required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
More disclaimer info: More
disclaimer
and
disclosure
info
https://www.investorideas.com/About/Disclaimer.asp Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media, podcast services at
Investorideas.com for AI stocks
Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by
copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to
buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content
creation and more. Contact each company directly regarding content and
press release questions.. More disclaimer info:
http://www.investorideas.com/About/Disclaimer.asp. This article is a third party guest post published content and not
the content of Investorideas.com . Learn more about posting your
articles at
http://www.investorideas.com/Advertise/
